# Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

> **NCT01974895** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 316 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** FluLaval® Quadrivalent
- **BIOLOGICAL:** Fluzone®

## Key facts

- **NCT ID:** NCT01974895
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-23
- **Primary completion:** 2014-02-27
- **Final completion:** 2014-07-03
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2018-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01974895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01974895, "Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01974895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*